Eiger and the FDA Have Met to Disucss Lonafarnib, an Investigational Treatment For Progeria
jniittymaa0 / Pixabay

Eiger and the FDA Have Met to Disucss Lonafarnib, an Investigational Treatment For Progeria

The US Food and Drug Administration and Eiger BioPharmaceuticals, Inc. have met to discuss lonafarnib, a drug being investigated as a potential treatment for Hutchinson-Gilford Progeria Syndrome. For more detailed…

Continue Reading Eiger and the FDA Have Met to Disucss Lonafarnib, an Investigational Treatment For Progeria
Researchers are Looking for People Diagnosed with Multiple Sclerosis to Take Part in a Phone App Study
JESHOOTScom / Pixabay

Researchers are Looking for People Diagnosed with Multiple Sclerosis to Take Part in a Phone App Study

Researchers are looking for participants to take part in a study investigating whether a mobile app could benefit patients with multiple sclerosis. For more information about this study and how…

Continue Reading Researchers are Looking for People Diagnosed with Multiple Sclerosis to Take Part in a Phone App Study
HNF to Meet With The FDA to Discuss Treatments for Charcot-Marie-Tooth Disease
Free-Photos / Pixabay

HNF to Meet With The FDA to Discuss Treatments for Charcot-Marie-Tooth Disease

According to a story from PR Newswire, the Hereditary Neuropathy Foundation (HNF) recently announced that it will be conducting a meeting with the US Food and Drug Administration (FDA). This…

Continue Reading HNF to Meet With The FDA to Discuss Treatments for Charcot-Marie-Tooth Disease
A Woman With Atypical Hemolytic Uremic Syndrome Was Brought Back From The Brink
paulbr75 / Pixabay

A Woman With Atypical Hemolytic Uremic Syndrome Was Brought Back From The Brink

According to a story from The Chicago Tribune, Darnesha Bankston, age 23, was rushed to the hospital just before Christmas last year with a bunch of severe, life threatening symptoms.…

Continue Reading A Woman With Atypical Hemolytic Uremic Syndrome Was Brought Back From The Brink
Global Phase 3 Trial For Experimental Myasthenia Gravis Treatment to Begin Before The End of The Year
mwooten / Pixabay

Global Phase 3 Trial For Experimental Myasthenia Gravis Treatment to Begin Before The End of The Year

According to a story from Euroinvestor, the biotechnology company argenx recently announced that it has gotten correspondence from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in regards to the design…

Continue Reading Global Phase 3 Trial For Experimental Myasthenia Gravis Treatment to Begin Before The End of The Year
Close Menu